Skip to main navigation Skip to search Skip to main content

Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis

  • R. Porat
  • , H. N. Paddock
  • , S. D. Schwaitzberg
  • , R. J. Connolly
  • , T. Wilkens
  • , J. R. Dasch
  • , M. P. Gascon
  • , J. S. Hutchison
  • , A. Ythier
  • , D. Wallach
  • , C. A. Dinarello
  • Tufts-New England Medical Center

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Abstract

Objective: To examine the effect of glycosylated recombinant human tumor necrosis factor binding protein-1 (r-hTNF binding protein-1), the extracellular domain of the tumor necrosis factor receptor p55 produced in mammalian cells, in a rabbit model of circulatory shock due to Escherichia coli. Design: Prospective, randomized, controlled trial. Setting:University hospital research laboratory.Subjects: Eighteen female, New Zealand white rabbits. Interventions: Anesthetized rabbits, infused with E. coli (109 organisms/kg), were pretreated with either r-hTNF binding protein-1 or saline. Mean arterial pressure, central venous pressure, cardiac output, and heart rate were recorded every 20 mins for 1 hr before, and for 4 hrs after, the infusion of E. coli. Blood samples were obtained at 1-hr intervals for platelet count and white blood cell count, r-hTNF binding protein-1, and tumor necrosis factor (TNF) measurements. Measurements and Main Results: Administration of r-hTNF binding protein-1 resulted in improvement of mean arterial pressure, cardiac output, and systemic vascular resistance, as compared with the vehicle-treated group (p < .05). Treatment with r-hTNF binding protein-1 was associated with 100% survival, as compared with 55.6% of the saline-treated rabbits (p < .05). Approximately 85% of r-hTNF binding protein-1 was cleared from the circulation 1 hr after the bolus injection (from 171 ± 27 μg/mL at time = 0, to 27 ± 4 μg/mL at 60 mins, decreasing to 6 ± 2 mg/mL for the next 3 hrs). The r-hTNF binding protein-1-treated rabbits had lower serum TNF bioactivity during the first 2 hrs (p < .01). The decreased bioactivity of TNF was confirmed by a specific radioimmunoassay for rabbit TNF. However, at 4 hrs, the vehicle-treated rabbits had lower serum bioactive TNF concentrations (p < .05). The decrease in TNF concentrations in the r-hTNF binding protein-1-treated rabbits resulted from decreased production and, in part, from carry-over of r-hTNF binding protein-1 into the bioassay. Conclusions: Treatment with r-hTNF binding protein-1 improved hemodynamic variables and survival of E. coli-challenged rabbits. Administration of r-hTNF binding protein-1 suppressed bioactivity of TNF in the circulation of these rabbits, and the production of TNF as well.

Original languageEnglish
Pages (from-to)1080-1089
Number of pages10
JournalCritical Care Medicine
Volume23
Issue number6
DOIs
StatePublished - 1995

Keywords

  • bacteria
  • critical illness
  • cytokines
  • endotoxin
  • hemodynamics
  • radioimmunoassay
  • receptors
  • sepsis
  • septic shock
  • tumor necrosis factor

Fingerprint

Dive into the research topics of 'Glycosylated recombinant human tumor necrosis factor binding protein-1 reduces mortality, shock, and production of tumor necrosis factor in rabbit Escherichia coli sepsis'. Together they form a unique fingerprint.

Cite this